RecruitingPhase 2NCT07745361

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

MODeFIRe-1 (Molecular Degrader for Inhibitor Resistance): A Phase 2, Open-Label, Multicenter Study of Oral MRT-2359 in Combination With Apalutamide in Patients With Castration-Resistant Prostate Cancer

Sponsor

Monte Rosa Therapeutics, Inc

Enrollment

25 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer Prostate Cancer (Adenocarcinoma)Castration-Resistant Prostate Cancer (CRPC)Castration-resistant Prostate Cancer

Summary

This Phase 2, open-label, multicenter study is conducted in patients with castration-resistant prostate cancer. Patients in this study receive MRT-2359, an investigational oral medicine, in combination with apalutamide, an oral medicine used to treat prostate cancer. The main purpose of the study is to assess whether this treatment combination can lower prostate-specific antigen (PSA) The study will also evaluate the safety and tolerability of the treatment combination and assess additional measures of anti-tumor activity.

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Apalutamide and a drug called Oral MRT-2359 for people with castration-resistant prostate cancer (crpc), castration-resistant prostate cancer, and other related conditions. The study is currently recruiting participants at 14 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOral MRT-2359

Orally administered tablets of MRT-2359

DRUGApalutamide

Orally administered apalutamide

Locations(14)

START Los Angeles

Los Angeles, California, United States

Hoag Memorial Hospital Presbyterian

Newport Beach, California, United States

Rocky Mountain Cancer Center

Colorado Springs, Colorado, United States

Kansas University Cancer Center

Kansas City, Kansas, United States

University of Maryland Greenebaum Cancer Center

Baltimore, Maryland, United States

Henry Ford

Novi, Michigan, United States

XCancer Omaha

Omaha, Nebraska, United States

START New Jersey

East Brunswick, New Jersey, United States

Levine Cancer Institute

Charlotte, North Carolina, United States

Lancaster Urology

Lancaster, Pennsylvania, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

START Mountain Region

West Valley City, Utah, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

University of Washington Medical Center

Seattle, Washington, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07745361

Related Trials

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)

NCT060857291 location

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803342 locations

Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer

NCT075481648 locations

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

NCT056166501 location

Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

NCT025942021 location